(Q30409505)

English

Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

object named as

Jenish Patel

9

0 references

Thomas P. Monath

6

object named as

Thomas Monath

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jacqueline M. Katz

11

object named as

Jacqueline M Katz

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jessica A Belser

8

object named as

Jessica A Belser

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jeffery Fairman

3

object named as

Jeffery Fairman

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Libo Dong

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Feng Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

David K Hong

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

David B Lewis

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

John F Warner

7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Kathy Hancock

10

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Xiuhua Lu

12

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

12 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

254-264

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Avian flu to human influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Update on avian influenza A (H5N1) virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

The public health impact of avian influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Host range restriction and pathogenicity in the context of influenza pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

A novel vaccine adjuvant for recombinant flu antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

CD4 T cell responses to influenza infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

TLR9 signaling in B cells determines class switch recombination to IgG2a

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Immune mechanisms of protection: can adjuvants rise to the challenge?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

The unmet need in the elderly: designing new influenza vaccines for older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Role of the B-cell response in recovery of mice from primary influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Fcgamma receptors as regulators of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Interleukin 4 induces synthesis of IgE and IgG4 in human B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.103

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.10.103

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30409505&oldid=1854450980"